73 related articles for article (PubMed ID: 32303902)
1. Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.
Murakami T; Tanaka N; Takamatsu K; Hakozaki K; Fukumoto K; Masuda T; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Sawada K; Imamura T; Mizuno R; Oya M
Cancer Immunol Immunother; 2021 Oct; 70(10):3001-3013. PubMed ID: 34259900
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological and prognostic significances of EZH2 expression in urological cancers: A meta‑analysis and bioinformatics analysis.
Bai YK; Sun J; Wang YS; Zheng N; Xu QL; Wang Y
Oncol Lett; 2023 Jul; 26(1):315. PubMed ID: 37346412
[TBL] [Abstract][Full Text] [Related]
3. H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets.
Burlibasa L; Nicu AT; Chifiriuc MC; Medar C; Petrescu A; Jinga V; Stoica I
Front Cell Dev Biol; 2023; 11():1181764. PubMed ID: 37228649
[TBL] [Abstract][Full Text] [Related]
4. EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma.
Xu S; Ma B; Feng X; Yao C; Jian Y; Chen Y; Wang X; Xie H; Li L
Transl Androl Urol; 2023 Jan; 12(1):71-82. PubMed ID: 36760869
[TBL] [Abstract][Full Text] [Related]
5. Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG).
Lyu C; Wang L; Stadlbauer B; Noessner E; Buchner A; Pohla H
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077742
[TBL] [Abstract][Full Text] [Related]
6. Napsin A Expression in Human Tumors and Normal Tissues.
Weidemann S; Böhle JL; Contreras H; Luebke AM; Kluth M; Büscheck F; Hube-Magg C; Höflmayer D; Möller K; Fraune C; Bernreuther C; Rink M; Simon R; Menz A; Hinsch A; Lebok P; Clauditz T; Sauter G; Uhlig R; Wilczak W; Steurer S; Burandt E; Krech R; Dum D; Krech T; Marx A; Minner S
Pathol Oncol Res; 2021; 27():613099. PubMed ID: 34257582
[No Abstract] [Full Text] [Related]
7. Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types.
Erokhin M; Chetverina O; Győrffy B; Tatarskiy VV; Mogila V; Shtil AA; Roninson IB; Moreaux J; Georgiev P; Cavalli G; Chetverina D
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202528
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
[TBL] [Abstract][Full Text] [Related]
9. EZH2 as a Regulator of CD8+ T Cell Fate and Function.
Stairiker CJ; Thomas GD; Salek-Ardakani S
Front Immunol; 2020; 11():593203. PubMed ID: 33117406
[TBL] [Abstract][Full Text] [Related]
10. High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Eichenauer T; Simmendinger L; Fraune C; Mandelkow T; Blessin NC; Kluth M; Hube-Magg C; Möller K; Clauditz T; Weidemann S; Dahlem R; Fisch M; Riechardt S; Simon R; Sauter G; Büscheck F; Rink M
World J Urol; 2021 Feb; 39(2):481-490. PubMed ID: 32303902
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
12. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
